Nevertheless, the clinical use of Ipilimumab (and similar antibodies) in cancer immunotherapy is limited by the fact that it is effective in only a small fraction of cancer patients and, furthermore, it exerts a substantial and often severe immunotherapy-related adverse effect (irAE) in the form of inflammatory and autoimmune manifestations, necessitating cessation of treatment in some patients. Thus, there is an urgent need to understand the cellular and molecular basis of irAEs associated with the therapeutic use of anti-CTLA-4 antibodies. Such understanding would allow the development of antibodies that retain their much desired CITE, but are devoid of deleterious irAE.
For a long time, the therapeutic effect of anti-CTLA-4 antibodies has been ascribed to their ability to block the interaction between CTLA-4 and its ligands, CD80/86, thus favoring the interaction of these ligands with the competing CD28 costimulatory receptor to result in effective activation of Tresp cells. This mode of action led to the concept of checkpoint blockade as the mechanistic basis for the CITE of anti-CTLA-4 antibodies, based on early findings that such antibodies blocked the binding of soluble CD80/86 to surface-bound CTLA-4.
8 However, this model has recently been challenged by two 2018 reports, demonstrating that Ipilimumab did not, in fact, block the interaction of immobilized or cell-bound CD80/86 with CTLA-4, or the transendocytosis of these ligands from DCs. 9, 10 Furthermore, engineered antibodies that lost their ability to block the CTLA-4-CD80/86 interaction fully retained their CITE by depleting intratumoral Tregs. These studies further demonstrated that the desirable CITE can be uncoupled from the undesirable irAE. It is of interest that a novel Treg-intrinsic, CTLA-4-linked signaling pathway that we found to mediate contact-dependent suppression also appears to uncouple CITE from at least one form of experimental irAE, i.e., autoimmune colitis.
11
In an elegant study recently published in Cell Research, Zhang et al. took a substantial step forward by elucidating the molecular mechanism responsible for the irAE. 12 They demonstrate that, while irAE-prone antibodies such as Ipilimumab directly associate with surface CTLA-4 for lysosomal degradation in a pHindependent manner, the engineered non-irAE-prone antibodies dissociate from CTLA-4 after endocytosis in endosomal vesicles with lower pH (Fig. 1) . The dissociated CTLA-4 subsequently interacts with LRBA, a vesicle trafficking chaperone, allowing its recycling to the cell surface. To further validate this mode of action, the authors went on to engineer Tremelimumab, an irAEprone anti-CTLA-4 antibody that has yet to gain FDA approval, to increase its pH sensitivity. This alteration allowed the resulting Published online: 12 July 2019 pH-sensitive antibodies to disengage from CTLA-4 in acidic endosomal vesicles, allowing CTLA-4 to recycle to the cell surface rather than being targeted for degradation. They also demonstrate that such antibodies display minimal, if any, irAE and, importantly, are more effective in Treg depletion and rejection of large established tumors in mice. Despite these encouraging in vivo studies, it remains to be determined whether similar pHsensitive antibodies would exert a CITE in other tumors, especially in human cancer patients, since the acidic tumor microenvironment (a result of Warburg effect) may adversely affect the binding efficiency of such antibodies to CTLA-4. Nonetheless, these findings open the door for rationally designing tailor-made antibodies with abrogated irAE and enhanced CITE. The next obvious step would be to translate these exciting findings from basic discovery to clinical proof of concept. Hence, we can be cautiously optimistic about the future of anti-CTLA-4 cancer immunotherapy, which, despite perhaps not functioning via true "checkpoint blockade", could nevertheless represent an important step forward in immune-based cancer therapies.
